Therapeutics News and Research

RSS

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine.

22 Jul 2015

Expanded use for IntelliCap with further CE Mark for aspiration of fluids

The small, pill-shaped IntelliCap wireless medical device is opening up research opportunities into the impact of the small intestine microbiota on health and disease. For the first time, scientists have been able to obtain and analyse samples of the small intestine’s microbiome in a non-invasive way.

21 Jul 2015

Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

Dauntless Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC today announced a licensing agreement providing Dauntless' access to Aegis' Intravail drug delivery technology for an undisclosed oncology application and an option for three additional drugs.

21 Jul 2015

Alzheimer's Association recognizes four scientists with Lifetime Achievement Awards at AAIC 2015

The Alzheimer's Association recognizes four leading scientists for their contributions to advancing Alzheimer's disease and dementia research. The awards were presented during the opening session at the Alzheimer's Association International Conference 2015 in Washington, D.C.

21 Jul 2015

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital.

20 Jul 2015

Rowan University, Bamboo Therapeutics partner to combat Canavan disease

Rowan University and Bamboo Therapeutics, Inc. have entered into an asset transfer agreement to commercialize a novel gene therapy for the treatment of Canavan disease. A rare but devastating neurological disease that tragically takes a child's life by age 10, Canavan disease is one of the most common and complex degenerative cerebral diseases in infants.

17 Jul 2015

BUSM investigators receive MRA's Jackie King Young Investigator Awards

Boston University School of Medicine researchers Neil Joseph Ganem, PhD and Anurag Singh, PhD, each have received the Jackie King Young Investigator Awards from the Melanoma Research Alliance (MRA), the largest private funder of melanoma research. Both serve as assistant professors of pharmacology & experimental therapeutics and medicine.

17 Jul 2015

Novel cancer drug candidate developed in Singapore advances into clinical trials

A made-in-Singapore cancer drug has advanced into clinical trials, charting a milestone in Singapore's biomedical sciences initiative that will go towards improving the lives of cancer patients in Singapore, and worldwide.

17 Jul 2015

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.

16 Jul 2015

Protagonist Therapeutics closes $40 million Series C financing

Protagonist Therapeutics, Inc., a company developing novel, orally stable peptide therapeutics for gastrointestinal diseases and disorders, today announced the closing of a $40 million Series C financing.

16 Jul 2015

Gene therapy used for sight restoration also strengthens visual pathways in the brain

Since 2007, clinical trials using gene therapy have resulted in often-dramatic sight restoration for dozens of children and adults who were otherwise doomed to blindness. Now, researchers from the Perelman School of Medicine at the University of Pennsylvania and The Children's Hospital of Philadelphia, have found evidence that this sight restoration leads to strengthening of visual pathways in the brain, published this week in Science Translational Medicine.

16 Jul 2015

Georgia researchers develop new tools to genetically manipulate parasite that causes cryptosporidiosis

Researchers at the University of Georgia have developed new tools to study and genetically manipulate cryptosporidium, a microscopic parasite that causes the diarrheal disease cryptosporidiosis.

16 Jul 2015

New research offers potential for early intervention to prevent neurodegenerative diseases

New research led by investigators at Beth Israel Deaconess Medical Center provides the first direct evidence linking traumatic brain injury to Alzheimer's disease and chronic traumatic encephalopathy (CTE) -- and offers the potential for early intervention to prevent the development of these debilitating neurodegenerative diseases.

16 Jul 2015

Loss of dietary diversity contributes to rise in obesity, Type 2 diabetes and other diseases

A loss of dietary diversity during the past 50 years could be a contributing factor to the rise in obesity, Type 2 diabetes, gastrointestinal problems and other diseases, according to a lecture by Mark Heiman, vice president and chief scientific officer at MicroBiome Therapeutics, at IFT15: Where Science Feeds Innovation hosted by the Institute of Food Technologists in Chicago.

16 Jul 2015

Two chemical compounds effectively inhibit growth of brain cancer cells and breast tumors

Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.

16 Jul 2015

Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.

15 Jul 2015

Agilent and BTI collaborate to address a critical need in biopharmaceutical industry

The collaboration will address a gap in analytical tests and standards applied for drugs based on glycoproteins, which now form the majority of approved biopharmaceutical drugs. Current analytical methods for characterizing glycans are time-consuming and difficult to deploy in commercial environments. They are also limited in their ability to detect and analyze minor glycan species.

15 Jul 2015

New study reveals highly promising approach to coating tissue engineered constructs

A new study showing the ability to apply a thin coating of viable respiratory epithelial cells to tissue engineered constructs using a commercially available spray device is especially promising for therapeutic approaches in development to repair or replace challenging structures such as trachea or bronchi.

15 Jul 2015

Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Isis Pharmaceuticals, Inc. announced today that it has earned a $2.15 million milestone payment from Biogen related to advancing the ongoing pivotal Phase 3 study (CHERISH) evaluating ISIS-SMN Rx in children with spinal muscular atrophy (SMA).

14 Jul 2015

Imperial Innovations secures EIB loan to support investment in UK biotech, life science sector

Imperial Innovations Group has secured a new GBP 50 million loan from the European Investment Bank to support investment in the UK biotech and life science sector.

14 Jul 2015

Therapeutics News and Research

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Expanded use for IntelliCap with further CE Mark for aspiration of fluids

Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

Alzheimer's Association recognizes four scientists with Lifetime Achievement Awards at AAIC 2015

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

Rowan University, Bamboo Therapeutics partner to combat Canavan disease

BUSM investigators receive MRA's Jackie King Young Investigator Awards

Novel cancer drug candidate developed in Singapore advances into clinical trials

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Protagonist Therapeutics closes $40 million Series C financing

Gene therapy used for sight restoration also strengthens visual pathways in the brain

Georgia researchers develop new tools to genetically manipulate parasite that causes cryptosporidiosis

New research offers potential for early intervention to prevent neurodegenerative diseases

Loss of dietary diversity contributes to rise in obesity, Type 2 diabetes and other diseases

Two chemical compounds effectively inhibit growth of brain cancer cells and breast tumors

Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Agilent and BTI collaborate to address a critical need in biopharmaceutical industry

New study reveals highly promising approach to coating tissue engineered constructs

Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Imperial Innovations secures EIB loan to support investment in UK biotech, life science sector

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News